0001209191-15-076188.txt : 20151019
0001209191-15-076188.hdr.sgml : 20151019
20151019192842
ACCESSION NUMBER: 0001209191-15-076188
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20151015
FILED AS OF DATE: 20151019
DATE AS OF CHANGE: 20151019
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Kite Pharma, Inc.
CENTRAL INDEX KEY: 0001510580
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
BUSINESS ADDRESS:
STREET 1: 2225 COLORADO AVENUE
CITY: SANTA MONICA
STATE: CA
ZIP: 90404
BUSINESS PHONE: (310) 824-9999
MAIL ADDRESS:
STREET 1: 2225 COLORADO AVENUE
CITY: SANTA MONICA
STATE: CA
ZIP: 90404
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Roberts Margo R
CENTRAL INDEX KEY: 0001609643
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36508
FILM NUMBER: 151165243
MAIL ADDRESS:
STREET 1: 2225 COLORADO AVENUE
CITY: SANTA MONICA
STATE: CA
ZIP: 90404
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2015-10-15
0
0001510580
Kite Pharma, Inc.
KITE
0001609643
Roberts Margo R
C/O KITE PHARMA, INC.
2225 COLORADO AVENUE
SANTA MONICA
CA
90404
0
1
0
0
Chief Scientific Officer
Common Stock
2015-10-15
4
M
0
5500
0.70
A
7698
D
Common Stock
2015-10-15
4
M
0
645
17.00
A
8343
D
Common Stock
2015-10-15
4
S
0
361
60.08
D
7982
D
Common Stock
2015-10-15
4
S
0
1300
61.79
D
6682
D
Common Stock
2015-10-15
4
S
0
2800
62.62
D
3882
D
Common Stock
2015-10-15
4
S
0
1600
63.60
D
2282
D
Common Stock
2015-10-15
4
S
0
84
64.25
D
2198
D
Employee Stock Option (Right to Buy)
0.70
2015-10-15
4
M
0
5500
0.00
D
2023-10-07
Common Stock
5500
107625
D
Employee Stock Option (Right to Buy)
17.00
2015-10-15
4
M
0
645
0.00
D
2024-06-18
Common Stock
645
34523
D
The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 31, 2015.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $59.77 to $60.27, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $61.20 to $62.15, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $62.20 to $63.09, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $63.20 to $64.13, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
25% of the 150,000 shares subject to the stock option vested and became exercisable on August 19, 2014, and the remaining shares subject to the stock option vest and become exercisable in 36 monthly installments as of the last calendar day of each month following the initial vesting date.
25% of the 50,000 shares subject to the stock option vested and became exercisable on June 19, 2015, and the remaining shares subject to the stock option vest and become exercisable in 36 monthly installments as of the last calendar day of each month following the initial vesting date.
/s/ Dave Tanen, Attorney-in-Fact
2015-10-19